Ritu Chakravarti, PhD, associate professor of rheumatology, has been awarded a five-year R01 grant, totaling $3.2 million.
This grant will help fund Dr. Chakravarti's study of Interleukin-17A (IL-17A) signaling in autoimmune diseases. Interleukin-17A plays an important role in autoimmune diseases; however, the limited therapeutic utility of blocking IL-17A in rheumatoid arthritis points to the gaps in understanding its signaling mechanisms.
Previously, Dr. Chakravarti has participated in the publication of 14-3-3z-TRAF interaction-mediated novel regulation of IL-17A signaling. With the awarded grant, she now hopes to study the molecular mechanisms, consequences, and physiological relevance of 14-3-3z-TRAF interactions that will elucidate fundamental knowledge of IL-17A signaling and rheumatoid arthritis.
Read more about Dr. Chakravarti's research interests and publications here.
Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R01AI184880. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.